• {{ window.visitor.corporateClient.name }} Corporate solution {{ window.visitor.ipAccess.corporateClient.name }} {{ window.visitor.corporateClient.name }}

• Welcome to our Corporate client solution

  Here you can administrate your corporate solutions users.

• Welcome to your subscription for Life Science Nordic

• Welcome to our Corporate client solution

  Your IP is registered with the company mentioned above and provides access to Life Science Nordic.

• Manage corporate subscription {{company.name}}
• Click here to go to sign-up

Get access to all content on Life Science Nordic

No commitment or card information required

Already a subscriber? Log In

The European Medicines Agency (EMA) has validated Valneva’s and Pfizer’s application for approval of the companies’ Lyme disease vaccine, meaning it is now ready for formal scientific review.

August 14, 2026 1:59 PM

The companies’ marketing authorization application is based on results from a Phase III study showing an efficacy of more than 70 percent in preventing Lyme disease in individuals aged five years and older. More than 9,000 people took part in the study, which was conducted in areas with high Lyme disease prevalence in the United States, Canada and Europe.

BREAKING